Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition

Journal of Virology

Volumn 88, Issue 20, 2014, Pages 11726-11737

  Dowd, Kimberly A ^a   Mukherjee, Swati ^a   Kuhn, Richard J ^b   Pierson, Theodore C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; FURIN; PRM PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; FLAVIVIRUS; NONHUMAN; REPORTER VIRUS PARTICLE; VIRION; VIRUS INFECTIVITY; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WEST NILE FLAVIVIRUS; CHEMISTRY; DOSE RESPONSE; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; SERODIAGNOSIS;

ANTIBODIES, VIRAL; DENGUE VIRUS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEK293 CELLS; HUMANS; NEUTRALIZATION TESTS; WEST NILE VIRUS;

EID: 84907434113     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01140-14     Document Type: Article

References (56)

1. Artsob H, Gubler DJ, Enria DA, Morales MA, Pupo M, Bunning ML, Dudley JP. 2009. West Nile Virus in the New World: trends in the spread and proliferation of West Nile Virus in the Western Hemisphere. Zoonoses Public Health 56:357-369. http://dx.doi.org/10.1111/j.1863-2378.2008.01207.x.
2. Centers for Disease Control and Prevention. 2013. West Nile virus and other arboviral diseases-United States, 2012.MMWRMorb. Mortal. Wkly. Rep. 62: 513-517. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6225a1.htm.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http: //dx.doi.org/10.1038/nature12060.
4. Gubler DJ. 2012. The economic burden of dengue. Am. J. Trop. Med. Hyg. 86:743-744. http://dx.doi.org/10.4269/ajtmh.2012.12-0157.
5. Halstead SB. 2007. Dengue. Lancet 370:1644-1652. http://dx.doi.org/10.1016/S0140-6736(07)61687-0.
6. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG. 2007. Structure of immature West Nile virus. J. Virol. 81:6141-6145. http://dx.doi.org/10.1128/JVI.00037-07.
7. Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, Baker TS, Strauss JH, Kuhn RJ, Rossmann MG. 2003. Structures of immature flavivirus particles. EMBO J. 22:2604-2613. http://dx.doi.org/10.1093 /emboj/cdg270.
8. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, Kuhn RJ, Rossmann MG, Chen J. 2008. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319:1834-1837. http://dx.doi.org/10.1126/science.1153264.
9. Mukhopadhyay S, Kim BS, Chipman PR, Rossmann MG, Kuhn RJ. 2003. Structure of West Nile virus. Science 302:248. http://dx.doi.org/10.1126/science.1089316.
10. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725. http://dx.doi.org /10.1016/S0092-8674(02)00660-8.
11. Pierson TC, Diamond MS. 2012. Degrees of maturity: the complex structure and biology of flaviviruses. Curr. Opin. Virol. 2:168-175. http://dx.doi.org/10.1016/j.coviro.2012.02.011.
12. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. 2007. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5:518-528. http://dx.doi.org /10.1038/nrmicro1690.
13. Crill WD, Roehrig JT. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773. http://dx.doi.org/10.1128/JVI.75.16.7769-7773.2001.
14. Calvert AE, Kalantarov GF, Chang GJ, Trakht I, Blair CD, Roehrig JT. 2011. Human monoclonal antibodies to West Nile virus identify epitopes on the prM protein. Virology 410:30-37. http://dx.doi.org/10.1016/j.virol.2010.10.033.
15. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748. http://dx.doi.org/10.1126/science.1185181.
16. Della-Porta AJ, Westaway EG. 1978. A multi-hit model for the neutral-ization of animal viruses. J. Gen. Virol. 38:1-19. http://dx.doi.org/10.1099 /0022-1317-38-1-1.
17. Dowd KA, Pierson TC. 2011. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411:306-315. http://dx.doi.org/10.1016/j.virol.2010.12.020.
18. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135-145. http://dx.doi.org/10.1016/j.chom.2007.03.002.
19. Kaufmann B, Nybakken GE, Chipman PR, Zhang W, Diamond MS, Fremont DH, Kuhn RJ, Rossmann MG. 2006. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 103:12400-12404. http://dx.doi.org/10.1073/pnas.0603488103.
20. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437:764-769. http://dx.doi.org/10.1038/nature03956.
21. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80:9557-9568. http://dx.doi.org/10.1128/JVI.00080-06.
22. Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond MS, Fremont DH. 2012. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog. 8:e1002930. http://dx.doi.org/10.1371/journal.ppat.1002930.
23. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG, Fremont DH. 2009. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 28:3269-3276. http://dx.doi.org/10.1038/emboj.2009.245.
24. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4:e1000060. http://dx.doi.org/10.1371/journal.ppat.1000060.
25. Gould LH, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, de Silva AM, Diamond MS, Koski RA, Marasco WA, Fikrig E. 2005. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J. Virol. 79:14606-14613. http://dx.doi.org/10.1128/JVI.79.23.14606-14613.2005.
26. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS. 2007. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81:11828-11839. http://dx.doi.org/10.1128/JVI.00643-07.
27. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de Kruif J. 2006. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J. Virol. 80:6982-6992. http://dx.doi.org/10.1128/JVI.00551-06.
28. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7:e1002111. http://dx.doi.org/10.1371/journal.ppat.1002111.
29. Mukherjee S, Lin TY, Dowd KA, Manhart CJ, Pierson TC. 2011. The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases. J. Virol. 85:12067-12072. http://dx.doi.org/10.1128/JVI.05559-11.
30. Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS. 2011. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J. Virol. 85:11567-11580. http://dx.doi.org/10.1128/JVI.05859-11.
31. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-317. http://dx.doi.org/10.1038/nsmb.1382.
32. Rey FA. 2013. Dengue virus: two hosts, two structures. Nature 497:443-444. http://dx.doi.org/10.1038/497443a.
33. Witz J, Brown F. 2001. Structural dynamics, an intrinsic property of viral capsids. Arch. Virol. 146:2263-2274. http://dx.doi.org/10.1007 /s007050170001.
34. Li Q, Yafal AG, Lee YM, Hogle J, Chow M. 1994. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J. Virol. 68:3965-3970.
35. Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC. 2008. Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology 381:67-74. http: //dx.doi.org/10.1016/j.virol.2008.08.021.
36. Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW. 2006. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346:53-65. http://dx.doi.org/10.1016/j.virol.2005.10.030.
37. Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, Pierson TC. 2006. West Nile virus discriminates between DC-SIGN and DCSIGNR for cellular attachment and infection. J. Virol. 80:1290-1301. http: //dx.doi.org/10.1128/JVI.80.3.1290-1301.2006.
38. Randolph VB, Winkler G, Stollar V. 1990. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174:450-458. http://dx.doi.org/10.1016/0042-6822(90)90099-D.
39. Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC. 2014. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J. Virol. 88:7210-7220. http://dx.doi.org/10.1128/JVI.03690-13.
40. Organtini LJ, Makhov AM, Conway JF, Hafenstein S, Carson SD. 2014. Kinetic and structural analysis of coxsackievirus B3 receptor interactions and formation of the A-particle. J. Virol. 88:5755-5765. http://dx.doi.org /10.1128/JVI.00299-14.
41. Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, Diamond MS, Fremont DH, Pierson TC. 2013. The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states. J. Virol. 87:13729-13740. http://dx.doi.org/10.1128/JVI.02340-13.
42. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530. http://dx.doi.org/10.1038/nm1240.
43. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 80:12149-12159. http://dx.doi.org/10.1128/JVI.01732-06.
44. Bothner B, Dong XF, Bibbs L, Johnson JE, Siuzdak G. 1998. Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J. Biol. Chem. 273:673-676. http://dx.doi.org/10.1074/jbc.273.2.673.
45. Lewis JK, Bothner B, Smith TJ, Siuzdak G. 1998. Antiviral agent blocks breathing of the common cold virus. Proc. Natl. Acad. Sci. U. S. A. 95: 6774-6778. http://dx.doi.org/10.1073/pnas.95.12.6774.
46. Roy A, Post CB. 2012. Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity. Proc. Natl. Acad. Sci. U. S. A. 109:5271-5276. http://dx.doi.org/10.1073/pnas.1119174109.
47. Yewdell JW, Taylor A, Yellen A, Caton A, Gerhard W, Bachi T. 1993. Mutations in or near the fusion peptide of the influenza virus hemagglutinin affect an antigenic site in the globular region. J. Virol. 67:933-942.
48. Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ. 2009. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J. Virol. 83:7040-7048. http://dx.doi.org/10.1128/JVI.00557-09.
49. Murray JM, Aaskov JG, Wright PJ. 1993. Processing of the dengue virus type 2 proteins prM and C-prM. J. Gen. Virol. 74:175-182. http://dx.doi.org/10.1099/0022-1317-74-2-175.
50. Lei RX, Shi H, Peng XM, Zhu YH, Cheng J, Chen GH. 2009. Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection. Hepatology 50: 763-771. http://dx.doi.org/10.1002/hep.23062.
51. Sabo MC, Luca VC, Ray SC, Bukh J, Fremont DH, Diamond MS. 2012. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology 422:174-184. http://dx.doi.org/10.1016/j.virol.2011.10.023.
52. Fibriansah G, Ng TS, Kostyuchenko VA, Lee J, Lee S, Wang J, Lok SM. 2013. Structural changes in dengue virus when exposed to a temperature of 37°C. J. Virol. 87:7585-7592. http://dx.doi.org/10.1128 /JVI.00757-13.
53. Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, Rossmann MG. 2013. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc. Natl. Acad. Sci. U. S. A. 110:6795-6799. http://dx.doi.org/10.1073/pnas.1304300110.
54. Kostyuchenko VA, Chew PL, Ng TS, Lok SM. 2014. Near-atomic resolution cryo-electron microscopic structure of dengue serotype 4 virus. J. Virol. 88:477-482. http://dx.doi.org/10.1128/JVI.02641-13.
55. Luca VC, AbiMansour J, Nelson CA, Fremont DH. 2012. Crystal structure of the Japanese encephalitis virus envelope protein. J. Virol. 86:2337-2346. http://dx.doi.org/10.1128/JVI.06072-11.
56. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.